(Q34163495)

31 July 2017

1 reference

title

Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what, and why? (English)

1 reference

31 July 2017

0 references

Singletary SE

1

1 reference

31 July 2017

publication date

1 February 2001

1 reference

Journal of the American College of Surgeons

31 July 2017

published in

1 reference

31 July 2017

volume

192

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

220-230

1 reference

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Prognostic factors and therapeutic decisions in axillary node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Prognostic significance of occult lymph node metastases in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Lymphatic mapping and sentinel lymphadenectomy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Mapping a pathway for axillary staging: a personal perspective on the current status of sentinel lymph node dissection for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Learning sentinel node biopsy: results of a prospective randomized trial of two techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Intradermal blue dye to identify sentinel lymph-node in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Subareolar versus peritumoral injection for location of the sentinel lymph node

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

The sentinel node in breast cancer--a multicenter validation study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Sentinel lymph node involvement--a predictor for axillary node status with breast cancer--has the time come?

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Lessons learned from 500 cases of lymphatic mapping for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Meta-analysis of sentinel lymph node biopsy in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Detection and significance of occult metastases in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

NSABP halts B-14 trial: no benefit seen beyond 5 years of tamoxifen use

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Therapeutic implications of the sentinel lymph node in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2800%2900775-4

7 January 2021

10.1016/S1072-7515(00)00775-4

Identifiers

DOI

1 reference

31 July 2017

1 reference